Cargando…

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

A substantial minority of early breast cancer (EBC) patients relapse despite their tumors achieving pathologic complete response (pCR) after neoadjuvant therapy. We compared gene expression (BC360; nCounter(®) platform; NanoString) between primary tumors of patients with post-pCR relapse (N = 14) wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruzas, Simona, Gluz, Oleg, Harbeck, Nadia, Schmid, Peter, Cortés, Javier, Blohmer, Jens, Seiberling, Christine, Chiari, Ouafaa, Harrach, Hakima, Ataseven, Beyhan, Shenoy, Satyendra, Dyson, Mark H., Traut, Eugen, Theuerkauf, Ingo, Gebauer, Daniel, Kuemmel, Sherko, Reinisch, Mattea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964729/ https://www.ncbi.nlm.nih.gov/pubmed/35351903 http://dx.doi.org/10.1038/s41523-022-00403-3

Ejemplares similares

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
por: Reinisch, Mattea, et al.
Publicado: (2023)

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
por: Bruzas, Simona, et al.
Publicado: (2021)

Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers
por: Reinisch, Mattea, et al.
Publicado: (2021)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
por: Heil, Joerg, et al.
Publicado: (2018)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
por: Grote, Isabel, et al.
Publicado: (2022)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs
por: Ataseven, Beyhan, et al.
Publicado: (2014)

Efficacy and Safety of Auricular Acupuncture for the Treatment of Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial
por: Höxtermann, Melanie D., et al.
Publicado: (2021)

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022)

The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women’s response to integrative breast cancer treatment
por: Haller, Heidemarie, et al.
Publicado: (2021)

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial
por: Haller, Heidemarie, et al.
Publicado: (2019)

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2017)

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2019)

Autologous vs. implant-based breast reconstruction after skin- and nipple-sparing mastectomy—A deeper insight considering surgical and patient-reported outcomes
por: von Glinski, Maxi, et al.
Publicado: (2022)

The Partner Perspective on Autologous and Implant-Based Breast Reconstruction
por: von Glinski, Maxi, et al.
Publicado: (2023)

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
por: Dowsett, Mitch, et al.
Publicado: (2020)

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
por: Harbeck, Nadia, et al.
Publicado: (2021)

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
por: Graeser, Monika, et al.
Publicado: (2021)

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
por: Arboleda, Bolivar, et al.
Publicado: (2022)

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
por: Nitz, Ulrike, et al.
Publicado: (2020)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
por: Imterat, Majdi, et al.
Publicado: (2023)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors
por: Plett, Helmut, et al.
Publicado: (2020)

Judaism despite Christianity : the 1916 wartime correspondence between Eugen Rosenstock-Huessy and Franz Rosenzweig
por: Rosenstock-Huessy, Eugen, 1888-1973
Publicado: (2011)

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
por: Hofmann, Daniel, et al.
Publicado: (2013)

Temporal lobe abscess in a patient with isolated sphenoiditis
por: Stewart, Thomas A., et al.
Publicado: (2011)

The Search for the Ideal Female Breast: A Nationally Representative United-States-Census Study
por: Wallner, Christoph, et al.
Publicado: (2022)

Integrative oncology for breast cancer patients: introduction of an expert-based model
por: Dobos, Gustav J, et al.
Publicado: (2012)

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire
por: Herold, Natalie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gagnerls2vhp9s6gg1oe4cs0ac